Press Releases Year None20232022202120202019 Jun 07, 2023 Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials Jun 06, 2023 Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors Jun 02, 2023 Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights May 22, 2023 Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 09, 2023 Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results Apr 28, 2023 Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors Apr 18, 2023 Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting Mar 14, 2023 Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306 Feb 28, 2023 Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results Feb 02, 2023 Repare Therapeutics to Participate in Two Upcoming Investor Conferences Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last » Displaying 11 - 20 of 21